Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.2BCash, Jun 2026
+5%Share Count, 1 Year
Follow PTCT by emailGet an email when PTCT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PTCT, unsubscribe in one click. Privacy
📣 What PTCT Says Is Next
Q4 2026 · “A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.”
Company press release, Sep 21, 2026 · SEC filing
Q4 2026 · “PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy – Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease.”
Company press release, Sep 21, 2026 · SEC filing
Q4 2026 · “The nonclinical and clinical BLA modules have already been submitted as part of a rolling submission, with the CMC package expected to be submitted in Q4 2026.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
PTCT reported $2.2B in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PTCT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.